Practical information on the organisers’ website: http://assises-genetique.org/fr/programme/synoptique.
An overall definition of the tool, an analysis of the functional needs of future users and a prefiguration study were carried out.
The organisation of care is being put in place at the beginning of 2020.
The 13 first-line pre-indications validated by the Operating Committee correspond to clinical indications positively evaluated by the british National Health Service (NHS).
DEFIDIAG is a clinical trial in intellectual deficiency. The regulatory approvals of the French National Agency for Medicines and Health Products Safety (ANSM) and the French Data Protection Authority (CNIL) and the favourable opinion of the Institutional Review Board (CPP) have been obtained.
Dissemination of a questionnaire to the rare diseases and cancer care professionals for the submission of pre-indication projects. It explains: the interest of sequencing the complete genome in the patient care pathway, the technical constraints, the organisation to be set up and the expected volumes.
Dissemination of a questionnaire to the rare diseases and cancer care professionals for the submission of pre-indication projects. It explains: the interest of sequencing the complete genome in the patient care pathway, the technical constraints, the organisation to be set up and the expected volumes.
DEFIDIAG is a clinical trial in intellectual deficiency.
DEFIDIAG is a clinical trial in intellectual deficiency.
MULTISARC is a clinical trial of the MULTIPLI pilot project in advanced soft-tissue sarcomas.
In all, 108 firms took part, at some point, in all the industrial sector meetings (over 250 participants in total) including 37 large companies and 71 small- and medium-sized entreprises (SME).